Subsequent clinical trials showed that inflammatory markers in the circulation indicated the risk of T2DM, plasma TNF-α and IL-6 concentrations in patients with T2DM increased, and the anti-inflammatory medicine salicylate could improve the metabolic imbalance [6–8]. Here, IL6 is linked to type 2 diabetes mellitus.